Articles tagged with Vasculogenesis
A multidisciplinary team of world-leading experts is developing an off-the-shelf engineered product that could address liver failure in millions of patients. The ImPLANT project aims to create synthetic biology-based gene circuits in human induced pluripotent stem cells to drive cell differentiation into all required liver cell types.
A recent study published in The American Journal of Pathology has discovered that ADAM10 regulates abnormal blood vessel growth in the retina, which can cause vision loss or impairment. The findings suggest that targeting ADAM10 or its downstream effectors, such as Ephrin B2, may offer novel strategies for managing or preventing retina...
Scientists have created a vascularized organoid model of hormone-secreting cells in the pancreas, promising to improve diabetes research and cell-based therapies. The model, developed by Max Delbrück Center researchers, contains greater numbers of mature beta cells and secretes more insulin than non-vascularized counterparts.
Researchers developed porous dermal fillers that accelerate tissue healing and regeneration for diabetic wounds. The novel approach combining electrospinning and electrospraying technologies creates biocompatible microspheres that promote cell migration, granulation tissue formation, and neovascularization.
A study by Waseda University explores the effects of different vascularization strategies on brain organoids, improving cell differentiation and transcriptome profiles. Vascularized cerebral organoids exhibit a gene expression profile closer to fetal human brains than non-vascularized ones.
Researchers found a link between astrocytes from schizophrenic patients and reduced vascularization in the brain, which may contribute to the disease's metabolic flux. The study suggests that astrocytes could be a target for novel therapies to address schizophrenia.
In a mouse model of laser-induced CNV, RORα expression was highly increased in the choroidal/RPE complex post-laser, while loss or inhibition of RORα worsened CNV with increased lesion size and vascular leakage. RORα negatively regulates pathological CNV development by modulating angiogenic response and inflammatory environment.
Researchers explore the interactions between adipose tissues and surrounding blood vessels in connection with lipid metabolism and associated diseases. Targeting angiogenesis may provide a gateway for treating obesity, while its inhibition or promotion depends on the specific disease context.
Researchers found that CD146 expression is linked to retinal neovascularization in laser-induced CNV models. Anti-CD146 therapy showed promise in reducing neovascularization and improving vision outcomes.
Researchers developed a novel exosome-based treatment to deliver VEGF antibodies and suppress inflammation in ocular diseases. The therapy, rEXS-cL-aV, showed potent therapeutic efficacy in murine and nonhuman primate models.
Scientists at Scripps Research Institute have uncovered a potential new strategy for treating eye diseases, including age-related macular degeneration and diabetic retinopathy. A fragment of the protein CITED2 has been shown to reduce neovascularization while preserving healthy blood vessels in mouse models.
A new study estimates that nearly 9.6 million adults in the United States are highly myopic, or severely nearsighted, with over 41,000 suffering from a complication called myopic choroidal neovascularization that could cause long-term vision loss. Women appear to be at greater risk for this condition, making up half of those affected.
The study identified the DNA transcription factor SRF and its cofactors MRTF-A and MRTF-B as critical regulators of vascularization in the postnatal mouse eye. Loss of Srf led to microaneurysms and excess blood vessel formation similar to human retinal diseases.
Researchers identify ATRX as a crucial gene in maintaining genomic stability, preventing chromosomal mutations and rearrangements that can cause disease and aging. Atrx deficiency in mice leads to increased DNA damage, endocrine dysfunction, shortened lifespans, and degenerative phenotypes similar to human premature aging disorders.
Gene Signal's aganirsen shows promise in treating wet age-related macular degeneration and ischemic retinopathy by inhibiting neovascular growth. Clinical studies are scheduled to begin during the second quarter of 2012.
Ischemic retinopathy is characterized by uncontrolled blood vessel formation in the retina. Researchers found that inhibiting an enzyme can prevent this by restoring balance between 'good guy' and 'bad guy' growth factors.
A study published in July Ophthalmology journal confirms that failure and rejection of corneal transplants are more likely in patients with abnormal vessel growth before surgery. Researchers found that treating patients before transplant may improve success rates using growth-inhibiting drugs or gene transcription therapies.
Scientists at Scripps Research Institute have found that anti-oxidants in the diet can help preserve function by adding them to their diet. They also developed a novel gene therapy technique to offer an alternative option for arresting vision loss from eye diseases.
Phylonix Pharmaceuticals has been awarded a Phase II SBIR grant from the National Eye Institute to develop zebrafish models for eye diseases. The company aims to model various eye diseases, including diabetic retinopathy and age-related macular degeneration, using zebrafish models with high accuracy and speed.
Researchers found that macrophage entry into the eye encourages new vessel formation, while direct injection of macrophages significantly inhibits this process. This suggests regulators of macrophages may be a possible therapeutic target in AMD.
A new Georgia Tech micro-CT imaging technique helps tissue engineers develop better bone grafts by analyzing vascularization and mineralization. The technique provides high-resolution 3D images of bone repair, enabling researchers to optimize implant design and improve bone healing.
OXiGENE has expanded its research and development program in ophthalmology following a significant improvement in a patient with myopic macular degeneration. The patient's vision was restored to 20/20 after treatment with CA4P, a vascular targeting agent.
Researchers used transgenic mice to study CA4P's effect on choroidal neovascularization, finding it suppressed development and induced partial regression of established CNV. CA4P joins a growing list of drugs with potential as prophylactic agents for retinal and/or choroidal neovascularization.